| scholarly article | Q13442814 |
| P2093 | author name string | Mingzhao Xing | |
| P2860 | cites work | The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells | Q24519206 |
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer | Q28253304 | ||
| BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study | Q28289851 | ||
| A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns] | Q31942209 | ||
| Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. | Q33248741 | ||
| Thyroid nodules: clinical importance, assessment, and treatment. | Q33292935 | ||
| Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. | Q33296950 | ||
| BRAF(V600E) mutation and the biology of papillary thyroid cancer | Q33321820 | ||
| The impact of thyroid cancer and post-surgical radioactive iodine treatment on the lives of thyroid cancer survivors: a qualitative study | Q33399709 | ||
| Iodide handling by the thyroid epithelial cell | Q34382158 | ||
| BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer | Q34560988 | ||
| High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma | Q34572289 | ||
| Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. | Q34728843 | ||
| Increased incidence of thyroid carcinoma in france: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee | Q36009325 | ||
| BRAF mutation in thyroid cancer | Q36157661 | ||
| European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium | Q36489842 | ||
| Second primary malignancies in thyroid cancer patients | Q36671533 | ||
| Central lymph node dissection in differentiated thyroid cancer | Q36755450 | ||
| Management of low-risk differentiated thyroid cancer | Q36943006 | ||
| Management of patients with low-risk papillary thyroid carcinoma | Q36943014 | ||
| BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications | Q36972859 | ||
| Clinical features and therapeutic implication of papillary thyroid microcarcinoma | Q37019089 | ||
| Initial surgical management of thyroid cancer | Q37051626 | ||
| Efficacy of nodal dissection for treatment of persistent/recurrent papillary thyroid cancer | Q37057797 | ||
| An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer | Q37172786 | ||
| BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer | Q37242277 | ||
| Thyroid papillary microcarcinoma: a descriptive and meta-analysis study | Q37247453 | ||
| Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets | Q37397367 | ||
| Health-related quality of life in thyroid cancer survivors | Q39788580 | ||
| Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAF(V600E) mutation | Q39885341 | ||
| Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis | Q39915803 | ||
| Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer | Q39983584 | ||
| Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population | Q40052425 | ||
| Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer | Q40608157 | ||
| Prognostic factors in thyroid carcinomas | Q41706371 | ||
| BRAF mutation in papillary thyroid microcarcinoma: the promise of better risk management | Q43116732 | ||
| Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. | Q44003955 | ||
| Possible involvement of BRAFV600E in altered gene expression in papillary thyroid cancer | Q46133160 | ||
| The prevalence and prognostic value of BRAF mutation in thyroid cancer | Q46200580 | ||
| Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells | Q46395700 | ||
| BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer | Q46570559 | ||
| Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas | Q46922359 | ||
| Quality of life in cured patients with differentiated thyroid carcinoma. | Q46934993 | ||
| The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. | Q47570668 | ||
| Thyroid cancer incidence and socioeconomic indicators of health care access | Q51113140 | ||
| Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer | Q51805070 | ||
| A case-controlled study on the quality of life in a cohort of patients with history of differentiated thyroid carcinoma | Q51837455 | ||
| Preoperative staging of thyroid papillary carcinoma with ultrasonography | Q53348566 | ||
| Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. | Q53569559 | ||
| Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation | Q53675468 | ||
| High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes | Q54498240 | ||
| Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma | Q54505841 | ||
| Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. | Q54597071 | ||
| The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma | Q57762250 | ||
| Correlation Between Genetic Alterations and Microscopic Features, Clinical Manifestations, and Prognostic Characteristics of Thyroid Papillary Carcinomas | Q58053817 | ||
| Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis | Q58053853 | ||
| BRAFV600E mutation and p27kip1 expression in papillary carcinomas of the thyroid ≤1 cm and their paired lymph node metastases | Q60245904 | ||
| The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I− targeting to the membrane | Q60559931 | ||
| BRAF Mutations in Papillary Thyroid Carcinomas Inhibit Genes Involved in Iodine Metabolism | Q61951314 | ||
| BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation | Q64377520 | ||
| Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system | Q69458522 | ||
| Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer | Q72179282 | ||
| Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer | Q72849361 | ||
| Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality | Q73589651 | ||
| Thyroid reoperations: indications and risks | Q74760354 | ||
| Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry | Q77429537 | ||
| Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection | Q77861034 | ||
| Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer | Q79450454 | ||
| Lymph node metastases in differentiated thyroid cancer under 2 cm | Q79450463 | ||
| Outcomes of patients with differentiated thyroid carcinoma following initial therapy | Q79472924 | ||
| Presence of BRAF V600E in very early stages of papillary thyroid carcinoma | Q80416357 | ||
| Thyroid carcinoma | Q80595296 | ||
| Extent of surgery affects survival for papillary thyroid cancer | Q80838792 | ||
| Differentiated thyroid cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up | Q81215284 | ||
| Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake | Q81248210 | ||
| Expression of iodine metabolism genes in human thyroid tissues: evidence for age and BRAFV600E mutation dependency | Q81797099 | ||
| Clinical significance of metastasis to the central compartment from papillary microcarcinoma of the thyroid | Q82044773 | ||
| Management guidelines for patients with thyroid nodules and differentiated thyroid cancer | Q82293286 | ||
| Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment | Q83129859 | ||
| Increasing incidence of thyroid cancer in the United States, 1973-2002 | Q83310394 | ||
| Well-differentiated epithelial thyroid cancer management in the Asia Pacific region: a report and clinical practice guideline | Q83935331 | ||
| Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer | Q94332426 | ||
| P433 | issue | 1 | |
| P921 | main subject | papillary thyroid cancer | Q2292945 |
| P304 | page(s) | 86-93 | |
| P577 | publication date | 2009-10-31 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Molecular and Cellular Endocrinology | Q1573600 |
| P1476 | title | Prognostic utility of BRAF mutation in papillary thyroid cancer | |
| P478 | volume | 321 |
| Q30367068 | 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer |
| Q38459484 | Absence of Galectin-3 Immunostaining in Fine-Needle Aspiration Cytology Specimens from Papillary Thyroid Carcinoma Is Associated with Favorable Pathological Indices |
| Q34335277 | Activation of nuclear factor-κB contributes to growth and aggressiveness of papillary thyroid carcinoma |
| Q37921604 | Advances in surgical therapy for thyroid cancer |
| Q37621631 | Analysis of BRAF(V600E) mutation and DNA methylation improves the diagnostics of thyroid fine needle aspiration biopsies |
| Q33782121 | Application of molecular diagnostics to the evaluation of the surgical approach to thyroid cancer |
| Q44297101 | Assessment of cellularity, genomic DNA yields, and technical platforms for BRAF mutational testing in thyroid fine-needle aspirate samples |
| Q33884794 | Association between BRAF V600E Mutation and Ultrasound Features in Papillary Thyroid Carcinoma Patients with and without Hashimoto's Thyroiditis |
| Q37216703 | Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer |
| Q34501707 | Association of BRAFV600E mutation with clinicopathological features of papillary thyroid carcinoma: a study on a Chinese population |
| Q36360429 | BRAF Mutations in an Italian Regional Population: Implications for the Therapy of Thyroid Cancer. |
| Q27853042 | BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence |
| Q38174505 | BRAF mutation status in papillary thyroid carcinoma: significance for surgical strategy |
| Q42707282 | BRAFV600E mutation and papillary thyroid cancer: chicken or egg? |
| Q42761271 | Bilaterality in Papillary Thyroid Carcinoma: Does It Influence Prognosis? |
| Q55026989 | Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas. |
| Q37667684 | Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation |
| Q36493086 | Clinical significance of preoperative detection of serum p53 antibodies and BRAF(V600E) mutation in patients with papillary thyroid carcinoma |
| Q51018353 | Clinical utility of KAP-1 expression in thyroid lesions |
| Q41826094 | Contribution of the BRAF oncogene in the pre-operative phase of thyroid carcinoma |
| Q90903028 | Conventional Ultrasound, Immunohistochemical Factors and BRAFV600E Mutation in Predicting Central Cervical Lymph Node Metastasis of Papillary Thyroid Carcinoma |
| Q90671646 | Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer |
| Q38701744 | Cytotoxic and genotoxic effects of 131 I and 60 Co in follicular thyroid cancer cell (WRO) with and without recombinant human thyroid-stimulating hormone treatment |
| Q36194098 | Density of Tumor-Associated Macrophages Correlates with Lymph Node Metastasis in Papillary Thyroid Carcinoma |
| Q35731026 | Employing genetic markers to improve diagnosis of thyroid tumor fine needle biopsy |
| Q34226772 | Evaluation of PTEN, PI3K, MTOR, and KRAS expression and their clinical and prognostic relevance to differentiated thyroid carcinoma |
| Q36864736 | Evolving approaches to patients with advanced differentiated thyroid cancer |
| Q34169547 | Fine-needle aspiration of metastatic papillary thyroid carcinoma found in the liver |
| Q26765085 | Genetic Testing in Differentiated Thyroid Carcinoma: Indications and Clinical Implications |
| Q38100431 | Genetic mutations, molecular markers and future directions in research |
| Q38238835 | Genomic medicine for cancer prognosis |
| Q39203692 | Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas |
| Q30317867 | German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors |
| Q38408804 | Helix pomatia Agglutinin Binding Glycoproteins in Thyroid Tumors |
| Q34420079 | IQGAP1 Plays an Important Role in the Invasiveness of Thyroid Cancer |
| Q38787337 | Identification of somatic TERT promoter mutations in familial nonmedullary thyroid carcinomas |
| Q37188539 | Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAFV600E mutation in defining CND |
| Q91119967 | Impact of tumor-associated macrophages and BRAFV600E mutation on clinical outcomes in patients with various thyroid cancers |
| Q39267161 | Indications and extent of central neck dissection for papillary thyroid cancer: An American Head and Neck Society Consensus Statement |
| Q35977327 | Intracellular Signal Transduction and Modification of the Tumor Microenvironment Induced by RET/PTCs in Papillary Thyroid Carcinoma |
| Q91996944 | KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer |
| Q37408387 | Long intergenic non-coding RNA 271 is predictive of a poorer prognosis of papillary thyroid cancer |
| Q52871336 | Metadherin Expression is Associated with Extrathyroidal Extension in Papillary Thyroid Cancer Patients. |
| Q54575673 | Molecular Analysis of Thyroid Tumors |
| Q37924088 | Molecular genetics and diagnosis of thyroid cancer |
| Q34329018 | Molecular pathogenesis and mechanisms of thyroid cancer |
| Q47295202 | Molecular pathology of thyroid tumours of follicular cells: a review of genetic alterations and their clinicopathological relevance. |
| Q54977969 | Mps1 is associated with the BRAFV600E mutation but does not rely on the classic RAS/RAF/MEK/ERK signaling pathway in thyroid carcinoma. |
| Q82352404 | Muc-1 expression may help characterize thyroid nodules but does not predict patients' outcome |
| Q34660901 | Multikinase inhibitors use in differentiated thyroid carcinoma. |
| Q26782322 | Mutation Profile of Well-Differentiated Thyroid Cancer in Asians |
| Q86165664 | New Strategies in Diagnosing Cancer in Thyroid Nodules: Impact of Molecular Markers |
| Q37238757 | New developments in the diagnosis and treatment of thyroid cancer |
| Q33915384 | New insights in risk stratification of differentiated thyroid cancer. |
| Q48337801 | Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics |
| Q37550338 | Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases, and extra-nodal extension |
| Q38184374 | Prognostic biomarkers in thyroid cancer |
| Q92382824 | Prognostic implications of the BRAF-V600E mutation in papillary thyroid carcinoma based on a new cut-off age stratification |
| Q82182815 | Progress in Molecular Targeted Therapy for Thyroid Cancer: Vandetanib in Medullary Thyroid Cancer |
| Q26999887 | Progress in molecular-based management of differentiated thyroid cancer |
| Q35856673 | Promoter methylation of p16 and RASSF1A genes may contribute to the risk of papillary thyroid cancer: A meta-analysis |
| Q86553695 | Prophylactic lymph node dissection in papillary thyroid carcinoma: is there a place for lateral neck dissection? |
| Q38473950 | Pyrosequencing cut-off value identifying BRAFV600E mutation in fine needle aspiration samples of thyroid nodules. |
| Q39453153 | RAC1b overexpression in papillary thyroid carcinoma: a role to unravel |
| Q36365622 | Rearranged Anaplastic Lymphoma Kinase (ALK) Gene in Adult-Onset Papillary Thyroid Cancer Amongst Atomic Bomb Survivors |
| Q51272259 | Recent Advances in the Surgical Treatment of Differentiated Thyroid Cancer: A Comprehensive Review |
| Q36992782 | Recent Progress of Genome Study for Anaplastic Thyroid Cancer |
| Q53084563 | Relevance of BRAF and NRAS mutations in the primary tumor and metastases of papillary thyroid carcinomas |
| Q92384949 | Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-up |
| Q38390524 | Role of BRAF molecular analysis in the management of papillary thyroid carcinoma: analysis of cytological and histological samples |
| Q31114420 | Significance of the BRAF mRNA Expression Level in Papillary Thyroid Carcinoma: An Analysis of The Cancer Genome Atlas Data |
| Q35195766 | Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial |
| Q90336082 | Surgical approaches for papillary microcarcinomas: Turkey's perspective |
| Q36788057 | Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer |
| Q41233717 | Targeted next generation sequencing identifies somatic mutations and gene fusions in papillary thyroid carcinoma |
| Q35751013 | Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia |
| Q83537172 | The BRAF V600E Mutation in Papillary Thyroid Carcinoma Is Associated with Glucose Transporter 1 Overexpression |
| Q43740818 | The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis |
| Q35692478 | The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors |
| Q54564143 | The association of the BRAFV600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer |
| Q58453418 | The management of thyroid nodules and cancer in the molecular era |
| Q37962129 | The molecular diagnosis and management of thyroid neoplasms |
| Q84531197 | The relationship of the BRAF(V600E) mutation and the established prognostic factors in papillary thyroid carcinomas |
| Q36666417 | The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy |
| Q39242802 | Thyroid cancer cell lines: an overview. |
| Q57590701 | Thyroid cancer genetics: how close are we to personalizing clinical management? |
| Q38748774 | Tumour suppressive function of HUWE1 in thyroid cancer |
| Q38208701 | Update on the molecular diagnosis and targeted therapy of thyroid cancer |
| Q90162550 | VE1 Immunohistochemistry Improves the Limit of Genotyping for Detecting BRAFV600E Mutation in Papillary Thyroid Cancer |
| Q54493779 | Villous papillary thyroid carcinoma: a variant associated with marfan syndrome |
| Q37937236 | What if Many Follicular Variant Papillary Thyroid Carcinomas are not Malignant? a Review of Follicular Variant Papillary Thyroid Carcinoma and a Proposal for a New Classification |
Search more.